To engage NK cells toward CD30-positive tumor cells, a TandAb molecule, AFM13, with two binding sites for CD16A and two for CD30 was constructed.15, 118 This TandAb consisted of the affinity-matured human anti-CD16A and murine anti-CD30 variable domains. Here, TNFRSF8 is linked to neoplasm.